Discipline of Clinical Pharmacy, Universiti Sains Malaysia, Pulau Penang, Malaysia.
Faculty of Pharmacy, University of Sindh, Jamhoro, Pakistan.
PLoS One. 2023 May 23;18(5):e0285736. doi: 10.1371/journal.pone.0285736. eCollection 2023.
The response to the vaccine may vary among individuals. Hence, it is important to know how often individuals experience side effects after immunization against COVID-19.
This study aimed to assess the incidence of side effects following COVID-19 vaccination across different vaccine recipients in Southern Pakistan and identify the potential factors associated with these side effects in the population.
The survey was conducted across Pakistan through Google-forms Links from August to October 2021. The questionnaire included demographic information and COVID-19 vaccine information. Chi-square (x2) was performed for comparative analysis to check the significance level with P <0.05. The final analysis included 507 participants who had received COVID-19 vaccines.
Of the total 507 COVID-19 vaccines recipients, 24.9% received CoronaVac, 36.5% received BBIBP-CorV, 14.2% received BNT162b2, 13.8% received AZD1222, and 10.7% received mRNA-1273. The most prominent side effects after the first dose were fever, weakness, lethargy, and pain at the site of injection. Moreover, the most commonly reported side effects after the second dose were pain at the injection site, headache, body ache, lethargy, fever, chills, flu-like symptoms, and diarrhea.
Our results suggested that the side effects due to COVID-19 vaccination can vary between the first and second doses and type of COVID-19 vaccine. Our findings suggest continuing monitoring of vaccine safety and the importance of individualized risk-benefit assessment for COVID-19 immunization.
疫苗的反应可能因个体而异。因此,了解个体在接种 COVID-19 疫苗后出现副作用的频率很重要。
本研究旨在评估 COVID-19 疫苗在巴基斯坦南部不同疫苗接种者中的副作用发生率,并确定与人群中这些副作用相关的潜在因素。
该调查于 2021 年 8 月至 10 月通过 Google 表单链接在巴基斯坦各地进行。问卷包括人口统计学信息和 COVID-19 疫苗信息。采用卡方检验(x2)进行比较分析,以检查 P<0.05 的显著性水平。最终分析包括 507 名接受过 COVID-19 疫苗的参与者。
在总共 507 名接受 COVID-19 疫苗的接种者中,24.9%接受了 CoronaVac,36.5%接受了 BBIBP-CorV,14.2%接受了 BNT162b2,13.8%接受了 AZD1222,10.7%接受了 mRNA-1273。接种第一剂后最明显的副作用是发热、乏力、嗜睡和注射部位疼痛。此外,接种第二剂后最常报告的副作用是注射部位疼痛、头痛、全身疼痛、乏力、发热、寒战、流感样症状和腹泻。
我们的结果表明,COVID-19 疫苗接种引起的副作用在第一剂和第二剂之间以及 COVID-19 疫苗类型之间可能有所不同。我们的研究结果表明,需要继续监测疫苗安全性,并对 COVID-19 免疫进行个体化的风险-效益评估。